unknown
Stage
1
Investors
About
Immunicom develops novel immunotherapies, including its Immunopheresis® technology, designed to improve cancer treatment by enhancing patients' immune response while reducing typical side effects.
Explore Immunicom's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.